Long-term outcomes after radiofrequency ablation

A recent study published in Cancers this month provides evidence of the safety and effectiveness of image-guided percutaneous radiofrequency ablation (RFA) for the treatment of small renal cancers. One hundred and forty-nine (149) patients with an average age of 67 years had radiofrequency ablation for the treatment of a small renal cancer and were followed […]

read more

Evidence in favour of active surveillance for small renal masses

Two studies presented at the American Urological Association 2020 Virtual Experience this month provide evidence that active surveillance for small renal masses among older patients is as effective as surgery in terms of survival for patients with suspected renal cell carcinoma (RCC). In a study from Oxford University Hospitals 208 patients with 212 T1a small […]

read more

Percutaneous ablation for small renal masses

Current guidelines recommend partial nephrectomy as the preferred treatment option for small renal masses. Percutaneous ablation, such as radiofrequency ablation and cryoablation, are mainly considered for patients who are not suitable for surgery or who have other conditions (co-morbidities) that make them unfit for surgery. There is currently a lack of evidence comparing partial nephrectomy […]

read more

Renal mass biopsy in the management of kidney cancer

A review of the evolving field of the management of renal masses has been published in the Canadian Urological Association Journal. In this review, an expert panel from the Kidney Cancer Research Network of Canada provided the following recommendations: Renal mass biopsy should be offered to patients if the results of the biopsy will change […]

read more

Universal active surveillance for small renal masses

A study presented at the Society of Urologic Oncology (SUO) in Washington, USA last week concluded that universal initial active surveillance for patients with small renal masses (SRMs) less than 3 cm in diameter using predefined progression criteria can safely delay or avoid treatment for most patients. In the study, active surveillance was recommended for […]

read more

Partial nephrectomy for kidney cancer

At the recent Society of Urologic Oncology (SUO) conference in Washington, USA, Dr Steven Campbell reviewed the controversial topic of nephron-sparing surgery (partial nephrectomy) for stage cT1b-T2 kidney masses, i.e. tumours that are confined to the kidney but which are greater than 4 cm in diameter. Partial nephrectomy is recommended for small renal masses (stage […]

read more

IKCS 2019: Management of small renal masses

In this video interview, Dr Eric Singer from Rutgers Cancer Institute of New Jersey, USA discusses the management of small renal masses at the International Kidney Cancer Symposium (IKCS) in Miami earlier this month. Watch the video interview on Oncology Tube here

read more

Incidence and pattern of recurrence of kidney cancer after robotic partial nephrectomy

A recent study has shown the incidence and pattern of recurrence of renal cell carcinoma (RCC) in patients who underwent robotic partial nephrectomy for a small renal mass between September 2009 and March 2018. A total of 335 patients with a small renal mass underwent robotic partial nephrectomy, 269 patients of which were found to […]

read more

Outcomes following partial nephrectomy and percutaneous ablation for small renal masses

A study published in European Urology presents retrospective data from the Mayo Clinic in America regarding their experience with partial nephrectomy, percutaneous radiofrequency ablation (RFA) and percutaneous cryoablation for small renal masses (less than 4 cm, stage cT1). Long-term follow-up data from 1798 patients with primary cT1N0M0 renal tumours were treated with partial nephrectomy, RFA […]

read more

Extended duration of active surveillance of small renal masses

A recent study published in the Journal of Urology evaluated the outcomes of 103 patients with small renal masses (<6 cm) who were on active surveillance. The patients were followed for a median of 55.5 months, and in that time only 1% died of metastatic renal cell carcinoma (RCC). Of the 103 patients, 51.5% survived […]

read more
Showing 1 to 10 of 15 results
  TOP